Cargando…
肿瘤微环境内的免疫细胞、PD-1与EGFR-TKIs疗效关系新进展
In recent years, targeted therapy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) is the leading treatment modality for patients with advanced non-small cell lung cancer (NSCLC) and EGFR gene mutation. However, with the prolongation of the medication time, most of the patie...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973281/ https://www.ncbi.nlm.nih.gov/pubmed/29167008 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.11.09 |